Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants
WARRINGTON, Pa., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”) today announced it has...
Year: 2023
Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements
LITTLETON, Colo., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology...
Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis
Disc will obtain exclusive rights to MWTX-003 and other novel anti-TMPRSS6 antibodies in the United States, Europe and other territories...
Psyence Group Completes Export of Pharma Grade Psilocybin Extract to UK
TORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is...
Mindset Pharma Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate, MSP-1014, And Additional Family 1 Tryptamine Prodrug Candidates
TORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"),...
Flaggemelding relatert til PCIB
Myrlid AS har i dag, 20. januar 2023, solgt 450 000 aksjer i PCI Biotech Holding ASA ("Selskapet"). Som følge...
Ryan Davies Conducts CEO Chat with Leading Biotech IP Expert
CancerVAX CEO Ryan Davies speaks with Todd Kinard, a leading biotech intellectual property (IP) expert about how patents can be...
NFL Biosciences: CESTO II trial progressing on schedule
NFL Biosciences: CESTO II trial progressing on schedule Nine clinical sites active: more than 72% of the clinical trial participants...
Significant growth in revenues in 2022 & successfull acquisitions integration
Press Release Ecully, 20th January 2023 – 8:00 am 2022 revenues up 73% to €7.4 million "2022 financial year represents...
Hyloris Pharmaceuticals expands its Pipeline with a Product Candidate for a Mineral Deficiency in the Blood (hypophosphatemia)
Hyloris targets regulatory approval in Europe, with possible further extensionsAbout 5% of hospitalized patients is diagnosed with hypophosphatemia, with part...
MDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test
NEWS RELEASE –REGULATED INFORMATION20 JANUARY 2023, 1:00 am ET / 7:00 am CET MDxHealth Provides Updated and Supplemental...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022
NEW HAVEN, Conn., Jan. 19, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset...
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5%...
Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R),...
Procaps Announces Key Changes to the Board of Directors
International Corporate Executive and Attorney Alberto Eguiguren Correa Appointed to Board of Directors MIAMI and BARRANQUILLA, Colombia, Jan. 19, 2023...
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program
-Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular...
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
Study demonstrates targeted delivery devices functioned as designed when administered with food, potentially enabling non-fasted administrationSAN DIEGO, Jan. 19, 2023...
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
FDA sets PDUFA date of May 22, 2023SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:...
AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”...
AmMax Bio’s AMB-05X Receives EMA PRIME Designation for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
AMB-05X is the First and Only Investigational Drug Candidate to Receive PRIME Designation for the Treatment of TGCT PRIME Designation...